Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug ...

MSD and WuXi Biologics – which have been collaborating ... Alzheimer's therapy donanemab as well as other biologics, and AstraZeneca's recently opened, $360 million active pharmaceutical ...

AstraZeneca has confirmed that some of its ... and R&D centre in Shanghai and a network of supply sites in Wuxi, Taizhou, and Qingdao, employing around 16,000 people. China has expanded rapidly ...

AstraZeneca has multiple late-stage clinical ... On the CRO side, Big Pharma is reducing its exposure to China’s WuXi Biologics due to regulations and regulatory threats. That will benefit ...

• The Phase III segment dominated the market with the largest share in 2024. • The Phase I segment is expected to show the fastest growth during the forecast period. • The interventional study design ...

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...